RSCM
PBYI icon

Rock Springs Capital Management’s Puma Biotechnology PBYI Stock Holding History

Rock Springs Capital Management’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-587,400
Closed -$6.32M – 137
2019
Q3 		$6.32M Buy
587,400
+53,000
+10% +$572K 0.25% 93
2019
Q2 		$6.79M Buy
534,400
+76,400
+17% +$1.76M 0.25% 91
2019
Q1 		$17.8M Buy
458,000
+1,538
+0.3% +$47K 0.69% 51
2018
Q4 		$9.29M Sell
456,462
-31,138
-6% -$935K 0.44% 74
2018
Q3 		$22.4M Buy
487,600
+11,800
+2% +$569K 0.81% 42
2018
Q2 		$28.1M Buy
475,800
+62,900
+15% +$3.65M 1.08% 26
2018
Q1 		$28.1M Buy
412,900
+39,400
+11% +$2.95M 1.2% 25
2017
Q4 		$36.9M Buy
373,500
+43,500
+13% +$4.87M 1.68% 15
2017
Q3 		$39.5M Buy
330,000
+144,000
+77% +$13.4M 1.82% 12
2017
Q2 		$16.3M Buy
186,000
+91,500
+97% +$5.12M 0.82% 45
2017
Q1 		$3.52M Hold
94,500
– – 0.2% 104
2016
Q4 		$2.9M Buy
94,500
+25,000
+36% +$1.08M 0.19% 99
2016
Q3 		$4.66M Buy
69,500
+36,500
+111% +$1.85M 0.29% 90
2016
Q2 		$983K Buy
33,000
+1,500
+5% +$46.9K 0.07% 132
2016
Q1 		$925K Buy
31,500
+20,500
+186% +$926K 0.08% 123
2015
Q4 		$862K Sell
11,000
-4,900
-31% -$385K 0.07% 118
2015
Q3 		$1.2M Buy
15,900
+4,900
+45% +$463K 0.1% 118
2015
Q2 		$1.28M Sell
11,000
-13,250
-55% -$2.4M 0.09% 114
2015
Q1 		$5.73M Buy
24,250
+1,000
+4% +$214K 0.54% 67
2014
Q4 		$4.4M Buy
23,250
+2,750
+13% +$610K 0.51% 60
2014
Q3 		$4.89M Buy
+20,500
New +$4.21M 0.76% 42
2014
Q2 		– Sell
-3,728
Closed -$388K – 83
2014
Q1 		$388K Sell
3,728
-27,772
-88% -$3.26M 0.09% 75
2013
Q4 		$3.26M Buy
+31,500
New +$1.85M 1.17% 25

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rock Springs Capital Management's PBYI Position: Q4 2019 in Review

Rock Springs Capital Management sold out of Puma Biotechnology (PBYI) in Q4 2019, closing a stake of 587,400 shares — an estimated $6.32M sold.

Rock Springs Capital Management first reported a position in PBYI in Q4 2013 and held it in 23 quarters. The position peaked at $39.5M in Q3 2017. 133 funds tracked by Wall St. Rank hold PBYI as of Q4 2019.

  • Rock Springs Capital Management reported no remaining Puma Biotechnology position as of Q4 2019 after selling out during the quarter.
  • Rock Springs Capital Management sold 587,400 Puma Biotechnology shares in Q4 2019, an estimated $6.32M.
  • Rock Springs Capital Management first reported a position in Puma Biotechnology in Q4 2013 and held it in 23 quarters.
  • Rock Springs Capital Management's Puma Biotechnology position peaked at $39.5M in Q3 2017.
  • 133 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2019.

Based on Rock Springs Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.